Acquisition by Scangos George A of 22000 shares of Voyager Therapeutics at 12.57 subject to Rule 16b-3

VYGR Stock  USD 4.41  0.01  0.23%   
Slightly above 54% of Voyager Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Voyager Therapeutics suggests that many traders are impartial. Voyager Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Voyager Therapeutics. Many technical investors use Voyager Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Filed transaction by Voyager Therapeutics Director. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Acquisition of 22000 stock option (right to buy) at 12.57 of Voyager Therapeutics by Scangos George A on 9th of June 2025. This event was filed by Voyager Therapeutics with SEC on 2023-06-06. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Voyager Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Voyager Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Voyager Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Voyager Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Voyager Therapeutics Fundamental Analysis

We analyze Voyager Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Voyager Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Voyager Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Ratio

Current Ratio Comparative Analysis

Voyager Therapeutics is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Voyager Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Voyager Therapeutics stock to make a market-neutral strategy. Peer analysis of Voyager Therapeutics could also be used in its relative valuation, which is a method of valuing Voyager Therapeutics by comparing valuation metrics with similar companies.

Peers

Voyager Therapeutics Related Equities

ALLOAllogene Therapeutics   4.23   
0%
100.0%
TRDAEntrada Therapeutics   2.08   
0%
49.0%
ACHVAchieve Life   1.74   
0%
41.0%
AVIRAtea Pharmaceuticals   0.95   
0%
22.0%
SGMTSagimet Biosciences   0.16   
0%
3.0%
PYXSPyxis Oncology   0.23   
5.0%
0%
HUMAHumacyte   1.55   
36.0%
0%
ENTAEnanta Pharmaceuticals   1.60   
37.0%
0%
ARCTArcturus Therapeutics   1.96   
46.0%
0%
VNDAVanda Pharmaceuticals   2.22   
52.0%
0%

Additional Tools for Voyager Stock Analysis

When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.